CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR
SHANGHAI, April 4, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX:2616) delivered a poster of pre-clinical data of CS1003 at the 2019 American Association for Cancer Research (AACR) Annual Meeting. CS1003 is a humanized IgG4 PD-1 monoclonal antibody designed to block the interaction...
CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board
SHANGHAI, March 25, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) is pleased to announce the appointment of three internationally renowned oncologistsPaul A. Bunn, Jr., MD, Elizabeth M. Jaffee, MD, and Richard S. Finn, MD, as the company's Scientific Advisory Board (SAB) memb...
CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)
SUZHOU, China, March 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced thatChina's National Medical Products Administration (NMPA) has approved the clinical trial application to begin a Phase 1 trial inChina for BLU-667 (CS3009), a highly selective and potent ...
CStone received IND approval in China for HDAC6 inhibitor CS3003
SUZHOU, China, March 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals (Suzhou) Co., Ltd. ("CStone", stock code: 2616.HK) announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical tria...
CStone Pharmaceuticals listed on the Hong Kong Stock Exchange today
HONG KONG, Feb. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals (Stock code: 2616) today announced the listing of 186,396,000 shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price ofHK$12.00 per share, the net proceeds to be received by the Company are aboutHK$2,085...
